J&J won't pursue broader uses of Procrit

Johnson & Johnson says it's giving up its quest to expand the uses for its anemia drug Procrit, after a new clinical trial failed. Published in the New England Journal of Medicine today, the study didn't prove a decrease in red-blood-cell transfusions among critically ill patients taking Procrit.

The company had wanted to expand indications for Procrit to include all intensive-care patients with anemia, regardless of diagnosis. Currently, the drug is approved for anemic patients preparing for surgery or chemotherapy, and for those who also have HIV or kidney failure.

- read the the Wall Street Journal article on Procrit
see the report from Forbes

Related Articles:
New study points to danger of anemia drug. Report
FDA considers anemia drug trials on safety concerns. Report
FDA panel votes for restrictions on anemia drugs. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.